Download PDF
Thromb Haemost 1984; 51(02): 236-239
DOI: 10.1055/s-0038-1661066
Original Article
Schattauer GmbH Stuttgart

Outcome of Treatment of Deep-Vein Thrombosis with Urokinase: Relationship to Dosage, Duration of Therapy, Age of the Thrombus and Laboratory Changes

A D’Angelo
The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi and 3rd Department of Internal Medicine, University of Milano and Maggiore Hospital, Milano, Italy
,
P M Mannucci
The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi and 3rd Department of Internal Medicine, University of Milano and Maggiore Hospital, Milano, Italy
› Author Affiliations
Further Information

Publication History

Received 21 November 1983

Accepted 07 February 1984

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Forty-one patients with phlebographically proven DVT of the popliteal, femoral or iliac veins were treated with different regimens of urokinase (UK) given by continuous intravenous infusion. The four groups were comparable with respect to localization, extension and estimated age of the thrombi. Another phlebographic picture was taken within 48 hr after the end of UK infusion. Substantial lysis had occurred in 2 of 10 patients treated with 1500 U/kg/h for 2 days, in 4 of 11 treated with 2500/U/kg/h for 3 days, in 2 of 10 treated with 2500 U/kg/h for 7 days and in 4 of 10 treated with 4000 U/kg/h for 4 days. Only thrombi younger than 8 days could be lysed, with 61% (8/13) rate of lysis for thrombi less than 5 days old. Bleeding complications were observed more frequently with the higher doses and longer durations of therapy. The four treatment regimens all induced dose-dependent changes in fibrinogen, fibrin(ogen) degradation products, plasminogen and antiplasmin. Neither pre- nor postinfusion values of these parameters could differentiate patients with lysis from those without lysis. It is concluded that UK can provoke a high rate of thrombolysis of DVT treated early after the appearance of symptoms but that there is no relationship between UK-induced modifications of fibrinolysis and the outcome of therapy.

Keywords

Urokinase - Thrombolytic therapy - Streptokinase - Deep-vein thrombosis
 

  • References

  • 1 Hansen PF, Jørgensen M, Kjeldgaard NO, Ploug J. Urokinase - an activator of plasminogen from human urine. Experiences with intravenous application on twenty-two patients Angiology 1961; 12: 367-371
    CrossrefPubMedGoogle Scholar
  • 2 Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion J Lab Clin Med 1965; 65: 713-731
    PubMedGoogle Scholar
  • 3 Silver D. Urokinase in the management of acute arterial and venous thrombosis. Arch Surg 1968; 97: 910-916
    CrossrefPubMedGoogle Scholar
  • 4 Mavor GE, Ogston D, Galloway JM D, Karmody AM. Urokinase in iliofemoral venous thrombosis. Br J Surg 1969; 56: 571-574
    CrossrefPubMedGoogle Scholar
  • 5 Theiss W, Kriessmann A, Wirtzfeld A. Laborbefunde und klinische Ergebnisse bei thrombolytischer Langzeittherapie mit Urokinase. Herz/Kreis 1975; 7: 631-636
    PubMedGoogle Scholar
  • 6 Sharma GV R K, O’Connell DJ, Belko JS, Sasahara AA. Thrombolytic therapy in deep vein thrombosis. In: Thrombosis and Urokinase. Paoletti R, Sherry S. (eds) Academic Press; London: 1977. pp 181-189
    Google Scholar
  • 7 Tilsner V. Therapie mit Urokinase bei thrombotischen Verschliissen der Venen. In: Urokinase Workshop. Tilsner V. (ed) Papillon; Freiburg: 1978. pp 103-119
    Google Scholar
  • 8 Trübestein G, Brecht T, Etzel F. Ergebnisse der fibrinolytischen Therapie mit Urokinase bei älteren Phlebothrombosen. Dtsch Med Wschr 1979; 104: 1241-1242
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Juhan I, Calas MF, Buonocore M, Mathieu P, Isnard G, Cazenave B, Serradimigni A. Modifications in coagulation parameters induced by treatment associating urokinase (2000 U CTA/kg/h) with heparin. Thromb Haemostas 1979; 42: 945-954
    PubMedGoogle Scholar
  • 10 Niessner H, Lechner K, Thaler E. Laboratory and clinical evaluation of five urokinase schemes in acute and subacute deep vein thrombosis: a non-randomized study in 34 patients. In: Urokinase: Basic and Clinical Aspects. Mannucci PM, D’Angelo A. (eds) Academic Press; New York: 1982. pp 111-119
    Google Scholar
  • 11 Schöffel G, Zimmermann R, Harenberg J, Mori H. Blood coagulation changes during effective thrombolysis using urokinase and heparin. Thromb Res 1982; 25: 11-21
    CrossrefPubMedGoogle Scholar
  • 12 Thrombolytic therapy in thrombosis: a National Institutes of Health Consensus Development Conference. Ann Intern Med 1980; 93: 141-144
    CrossrefPubMed
  • 13 Bieger R, Boekhout-Mussert RJ, Hohmann F, Loeliger EM. Is streptokinase useful in the treatment of deep vein thrombosis. Acta Med Scand 1976; 199: 81-83
    PubMedGoogle Scholar
  • 14 Brandenberg E, Widmer MT, Schmitt HE, Widmer LK. Venenthrombose und postthrombotisches Syndrom. 5-Jahres-follow-up bei 278 Patienten. In: Fibrinolytische Therapie. Triibestein G, Etzel F. (eds) Schattauer; Stuttgart: 1983. pp 295-297
    Google Scholar
  • 15 Vermylen C, De Vreeker RA, Verstraete M. A quick quantitative enzymatic fibrinogen assay method: the fibrin polymerisation time (FPT). Clin Chim Acta 1963; 8: 428-434
    PubMedGoogle Scholar
  • 16 Hawiger J, Niewiarowski S, Gurewich V, Thomas DP. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. J Lab Clin Med 1970; 75: 93-108
    PubMedGoogle Scholar
  • 17 Abildgaard V, Lie M, Odegaard OR. Antihrombin (heparin cofactor) assay with »new« chromogenic substrates (S-2238 and Chromozym Th). Thromb Res 1977; 11: 549-553
    CrossrefPubMedGoogle Scholar
  • 18 Soria J, Soria C, Samama M. A plasminogen assay using a chromogenic synthetic substrate: results from clinical work and from studies of thrombolysis. In: Progress in Chemical Fibrinolysis and Thrombolysis. Vol.3. Davidson JF, Samama M, Desnoyers PC. (eds) Raven Press; New York: 1978. pp 337-346
    Google Scholar
  • 19 Teger-Nilsson AC, Friberger P, Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403-409
    CrossrefPubMedGoogle Scholar
  • 20 Mannucci PM, Sirchia G, Federici AB. Hemostasis testing during massive blood replacement. A study of 172 cases Vox Sang 1982; 42: 113-123
    PubMedGoogle Scholar
  • 21 Marbet GA, Eichlisberger R, Duckert F, Da Silva MA, Biland L, Widmer LK, Ritz R, Schmitt HE. Sequential treatment of deep leg vein thrombosis with porcine plasmin and low-dose streptokinase. Thromb Haemostas 1982; 48: 190-195
    PubMedGoogle Scholar
  • 22 Theiss W, Wirtzfeld A, Fink U, Maubach P. The success rate of fibrinolytic therapy in fresh and old thrombosis of the iliac and femoral veins. Angiology 1983; 34: 61-69
    CrossrefPubMedGoogle Scholar
  • 23 Bell WR, Meek AG. Guidelines for the use of thrombolytic agents. N Engl J Med 1977; 301: 1266-1270
    PubMedGoogle Scholar
  • 24 Marder VJ. The use of thrombolytic agents: Choice of patient, drug administration, laboratory monitoring. Ann Intern Med 1979; 90: 802-808
    CrossrefPubMedGoogle Scholar
  • 25 Dhall DP, Dawson AA, Mavor GE. Problems of resistant thrombolysis and early recurrent thrombosis in streptokinase therapy. Surg Gynecol Obstet 1978; 146: 15-20
    PubMedGoogle Scholar
  • 26 Schmutzler R, Roller F. Thrombolytic therapy. In: Recent advances in blood coagulation. Poller P. (ed) Churchill Ltd; London: 1969. pp 299-335
    Google Scholar
  • 27 Kakkar VV, Flanc C, Howe CT, O’Shea M, Flute PT. Treatment of deep vein thrombosis. A trial of heparin, streptokinase and arvin Br Med J 1969; 1: 806-810
    CrossrefPubMedGoogle Scholar
  • 28 Åstedt B, Robertson B, Haegar K. Experience with standardized streptokinase therapy of deep venous thrombosis. Surg Gynecol Obstet 1974; 139: 387-388
    PubMedGoogle Scholar
  • 29 Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-1029
    PubMedGoogle Scholar
  • 30 Duckert F, Muller G, Nyman D, Benz A, Prisender S, Madar G, Da Silva MA, Widmer LK, Schmitt HE. Treatment of deep vein thrombosis with streptokinase. Br Med J 1975; 1: 479-481
    CrossrefPubMedGoogle Scholar
  • 31 Tsapogas MJ, Peabody RA, Wu KT, Karmody AM, Devaraj KT, Eckert C. Controlled study of thrombolytic therapy in deep vein thrombosis. Surgery 1973; 74: 973-984
    PubMedGoogle Scholar
  • 32 Conard J, Samama M. Laboratory control of SK therapy. In: Present status of thrombosis. Its pathophysiology, diagnosis and treatment. Losito R. (ed) Schattauer; Stuttgart: 1973. pp 191-198
    Google Scholar
  • 33 Van de Loo JC W, Kriessmann A, Triibestein G, Knock K, de Swart CA M, Asbeck F, Marbet GA, Schmitt HE, Sewell AF, Duckert F, Theiss W, Ritz R. Controlled multicenter pilot study of urokinaseheparin and streptokinase in deep vein thrombosis. Thromb Haemostas 1983; 50: 660-663
    PubMedGoogle Scholar